Compare Stocks: SVA, VOR, MAZE, and TRAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$26.21 +1.3%	$28.69	$14.27 ▼ $53.65	$1.46B	2.17	386,888 shs	273,267 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.8	N/A	N/A
TRAX First Tracks Biotherapeutics	$40.46 -4.8%	$38.24	$14.72 ▼ $49.91	$1.45B	N/A	609,553 shs	456,216 shs
VOR Vor Biopharma	$25.05 +3.3%	$21.28	$6.50 ▼ $49.95	$1.48B	1.71	711,087 shs	421,584 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	0.00%	-4.48%	-8.13%	+7.99%	+72.55%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
TRAX First Tracks Biotherapeutics	0.00%	-3.34%	-10.70%	+143.73%	+4,045,999,900.00%
VOR Vor Biopharma	0.00%	+10.60%	+5.70%	+90.35%	-37.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
MAZE Maze Therapeutics	$26.21 +1.3%	$28.69	$14.27 ▼ $53.65	$1.46B	2.17	386,888 shs	273,267 shs
SVA Sinovac Biotech	$6.47	$6.47	$5.73 ▼ $8.75	$644.66M	0.8	N/A	N/A
TRAX First Tracks Biotherapeutics	$40.46 -4.8%	$38.24	$14.72 ▼ $49.91	$1.45B	N/A	609,553 shs	456,216 shs
VOR Vor Biopharma	$25.05 +3.3%	$21.28	$6.50 ▼ $49.95	$1.48B	1.71	711,087 shs	421,584 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
MAZE Maze Therapeutics	0.00%	-4.48%	-8.13%	+7.99%	+72.55%
SVA Sinovac Biotech	0.00%	0.00%	0.00%	0.00%	0.00%
TRAX First Tracks Biotherapeutics	0.00%	-3.34%	-10.70%	+143.73%	+4,045,999,900.00%
VOR Vor Biopharma	0.00%	+10.60%	+5.70%	+90.35%	-37.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
MAZE Maze Therapeutics	3.08	Buy	$66.00	151.81% Upside
SVA Sinovac Biotech	0.00	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	2.73	Moderate Buy	$63.00	55.71% Upside
VOR Vor Biopharma	2.82	Moderate Buy	$43.38	73.15% Upside

Current Analyst Ratings Breakdown

Latest SVA, VOR, MAZE, and TRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	TRAX First Tracks Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$57.00
8/24/2026	MAZE Maze Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	TRAX First Tracks Biotherapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$83.00
8/13/2026	TRAX First Tracks Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
8/13/2026	TRAX First Tracks Biotherapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$54.00 ➝ $95.00
8/13/2026	TRAX First Tracks Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$44.00 ➝ $57.00
8/13/2026	TRAX First Tracks Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$48.00 ➝ $65.00
8/13/2026	TRAX First Tracks Biotherapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$60.00 ➝ $70.00
8/12/2026	MAZE Maze Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$46.00
8/12/2026	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$18.00 ➝ $27.00
8/11/2026	VOR Vor Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D-) ➝ Sell (D+)

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
MAZE Maze Therapeutics	$167.50M	8.69	N/A	N/A	$7.38 per share	3.55
SVA Sinovac Biotech	$386.01M	1.67	$0.54 per share	11.89	$89.01 per share	0.07
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
MAZE Maze Therapeutics	-$131.12M	-$2.52	N/A	N/A	N/A	N/A	-34.94%	-30.18%	N/A
SVA Sinovac Biotech	-$59.68M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	-$1.84	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest SVA, VOR, MAZE, and TRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	TRAX First Tracks Biotherapeutics	-$0.74	-$0.95	-$0.21	-$0.95	N/A	N/A
8/11/2026	Q2 2026	MAZE Maze Therapeutics	-$0.76	-$0.76	N/A	-$0.76	N/A	N/A
8/11/2026	Q2 2026	VOR Vor Biopharma	-$0.69	-$0.80	-$0.11	-$1.16	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
MAZE Maze Therapeutics	N/A	N/A	N/A	N/A	N/A
SVA Sinovac Biotech	N/A	N/A	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
MAZE Maze Therapeutics	0.09	18.31	18.31
SVA Sinovac Biotech	0.04	6.07	5.97
TRAX First Tracks Biotherapeutics	N/A	14.28	14.28
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
MAZE Maze Therapeutics	N/A
SVA Sinovac Biotech	N/A
TRAX First Tracks Biotherapeutics	N/A
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
MAZE Maze Therapeutics	5.30%
SVA Sinovac Biotech	12.79%
TRAX First Tracks Biotherapeutics	N/A
VOR Vor Biopharma	0.27%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
MAZE Maze Therapeutics	121	55.55 million	52.61 million	N/A
SVA Sinovac Biotech	3,008	99.64 million	86.89 million	Optionable
TRAX First Tracks Biotherapeutics	N/A	35.73 million	N/A	N/A
VOR Vor Biopharma	140	59.16 million	59.00 million	N/A

SVA, VOR, MAZE, and TRAX Headlines

Recent News About These Companies

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

September 4 at 4:05 PM | globenewswire.com

Braidwell LP Has $10.55 Million Stake in Vor Biopharma Inc. $VOR

September 3 at 4:39 AM | marketbeat.com

Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR

September 3 at 3:12 AM | marketbeat.com

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

September 3 at 2:44 AM | americanbankingnews.com

Vor Biopharma Inc. (NASDAQ:VOR) Given Average Recommendation of "Moderate Buy" by Brokerages

September 3 at 2:43 AM | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Stock Price Up 6.2% - Time to Buy?

September 2, 2026 | marketbeat.com

Vor Bio To Participate in Upcoming September Conferences

September 1, 2026 | globenewswire.com

Wall Street Zen Upgrades Vor Biopharma (NASDAQ:VOR) to Hold

August 15, 2026 | marketbeat.com

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 14, 2026 | marketbeat.com

Vor Biopharma FY2030 EPS Forecast Reduced by HC Wainwright

August 13, 2026 | marketbeat.com

Wedbush Issues Positive Forecast for Vor Biopharma (NASDAQ:VOR) Stock Price

August 12, 2026 | marketbeat.com

Vor Biopharma (NASDAQ:VOR) Trading Down 6.5% on Disappointing Earnings

August 12, 2026 | marketbeat.com

Vor Biopharma Shares Drop After Q2 Results

August 11, 2026 | finance.yahoo.com

Vor Biopharma (NASDAQ:VOR) Posts Earnings Results

August 11, 2026 | marketbeat.com

Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 11, 2026 | finanznachrichten.de

Renaissance Technologies LLC Makes New $2.30 Million Investment in Vor Biopharma Inc. $VOR

August 11, 2026 | marketbeat.com

Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Rating of "Moderate Buy" from Analysts

August 9, 2026 | marketbeat.com

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

August 3, 2026 | globenewswire.com

Vor Biopharma: Vor Bio Appoints David Zaccardelli to Board of Directors

July 8, 2026 | finanznachrichten.de

Vor Bio Appoints David Zaccardelli to Board of Directors

July 7, 2026 | globenewswire.com

Vor Biopharma: A Financed Autoimmune Pivot With More Substance Than The Market Realizes

July 7, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SVA, VOR, MAZE, and TRAX Company Descriptions

Maze Therapeutics NASDAQ:MAZE

$26.21 +0.34 (+1.31%)

As of 09/4/2026 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization. Our Compass platform has been purpose-built to inform all phases of our drug discovery and development process through clinical trial design. We are currently advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD. Our goal is to bring novel precision medicines to patients to maximize our impact on human health. CKD is a serious, progressive condition that affects approximately 37 million patients in the United States, where it is expected to be the fifth most prevalent chronic disease by 2040. Current treatments for CKD consider patients as falling into clinical categories and focus on slowing the progression of disease, but do not target the underlying genetic drivers of disease. Our lead programs are designed to phenocopy, or mimic, the protective effects of certain genetic variants that are associated with reduced disease burden and improved kidney function in distinct groups of CKD patients. Our most advanced lead program, MZE829, is an oral, small molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD, which is estimated to affect over one million patients in the United States alone. Although the link between APOL1 variants and renal dysfunction has been known for over a decade, we have identified a new protective variant that underpins our therapeutic approach for MZE829 and may ultimately allow us to address a broader population of AKD than has previously been possible in the clinical setting. In October 2024, we reported results for our Phase 1 clinical trial of MZE829, in which we enrolled 111 healthy patients who received either single or multiple ascending doses of 20 mg to 480 mg of MZE829 administered daily. Treatment was well tolerated with no severe adverse events or serious adverse events reported in patients treated with single doses up to 480 mg and multiple doses of up to 350 mg daily for seven days. Dose-proportional pharmacokinetics, or PK, was observed with low variability (10-40%) across doses. We initiated a Phase 2 trial of MZE829 in November 2024 and expect to dose our first patient in the first quarter of 2025 and to report proof of concept data in the first quarter of 2026. Our second lead program, MZE782, is an oral, small molecule inhibitor of the solute transporter SLC6A19, a novel CKD target, with the potential to address approximately five million of the CKD patients in the United States with inadequate responses to currently available CKD therapies. Beyond its use as a potential standalone therapy, MZE782 may also provide a significant benefit to patients in combination with standard of care, including as a complementary treatment to current approved regimens or as an alternative option for those patients who do not adequately respond to today’s standard of care. We initiated a Phase 1 trial of MZE782 in September 2024 and expect to report initial data from this trial in the second half of 2025. In addition to CKD, we believe MZE782 may provide benefit to patients suffering from the genetically defined metabolic disease, phenylketonuria, or PKU. Following our ongoing Phase 1 trial of MZE782, we plan to conduct a parallel Phase 2 clinical trial to explore MZE782 as a potential treatment of PKU. Our Compass platform supports end-to-end variant identification and functionalization capabilities as well as advanced research tools and methodologies for drug development. We believe the process of variant functionalization, or understanding how genetic variants function to affect the course of disease, is a foundational aspect of precision medicine and one of the core capabilities that sets us apart from others in the field. We were incorporated under the laws of the State of Delaware on August 29, 2017, originally under the name Genetic Modifiers NewCo, Inc. We changed our name on July 5, 2018 to Modulus Therapeutics, Inc. and on September 25, 2018, to Maze Therapeutics, Inc. Our principal executive offices are located at 171 Oyster Point Blvd., Suite 300, South San Francisco, California.

Sinovac Biotech NASDAQ:SVA

$6.47 0.00 (0.00%)

As of 09/4/2026

Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza; coronavirus; varicella; and mumps. Its marketed products include Healive, an inactivated hepatitis A vaccine; Bilive, a combined inactivated hepatitis A and B vaccine; Anflu, a split viron influenza vaccine; Panflu, a vaccine against the H5N1 influenza virus; Panflu.1, a vaccine against the influenza A H1N1 virus; mumps vaccine to treat viral disease in human species; split viron pandemic influenza vaccine; and Inlive, an EV71 vaccine. The company also offers varicella, a vaccine to treat contagious infectious disease; pneumococcal polysaccharide vaccine, a vaccine to prevent streptococcus pneumoniae infections, such as pneumonia and septicemia; quadrivalent influenza vaccine, a vaccine to protect against two influenza A viruses and two influenza B viruses; and CoronaVac, a vaccine against COVID-19. In addition, its pipeline products include sabin inactivated polio vaccine, a vaccine to treat Poliomyelitis that has completed phase III clinical trial; and rubella vaccine. The company has collaboration agreements with GlaxoSmithKline Biologicals SA to develop combination vaccines containing measles for the China market; Tianjin CanSino Biotechnology Inc. to develop a pneumococcal vaccine; and Instituto Butantan to advance the clinical trials of CoronaVac, an inactivated vaccine candidate against COVID-19 to Phase III. Sinovac Biotech Ltd. was founded in 1993 and is headquartered in Beijing, the People's Republic of China.

First Tracks Biotherapeutics NASDAQ:TRAX

$40.46 -2.05 (-4.82%)

As of 09/4/2026 04:00 PM Eastern

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Vor Biopharma NASDAQ:VOR

$25.05 +0.81 (+3.34%)

As of 09/4/2026 04:00 PM Eastern

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVA, VOR, MAZE, and TRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVA, VOR, MAZE, and TRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVA, VOR, MAZE, and TRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SVA, VOR, MAZE, and TRAX Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Sinovac Biotech NASDAQ:SVA

First Tracks Biotherapeutics NASDAQ:TRAX

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SVA, VOR, MAZE, and TRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SVA, VOR, MAZE, and TRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SVA, VOR, MAZE, and TRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SVA, VOR, MAZE, and TRAX Company Descriptions

Maze Therapeutics NASDAQ:MAZE

Sinovac Biotech NASDAQ:SVA

First Tracks Biotherapeutics NASDAQ:TRAX

Vor Biopharma NASDAQ:VOR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools